文献速递贫血与红细胞疾病

铁螯合可挽救先天性红细胞生成性卟啉症患者的溶血性贫血和皮肤光敏感

Iron chelation rescues hemolytic anemia and skin photosensitivity in congenital erythropoietic porphyria.
PubMed 文献 · Blood · 2020-01-01

先天性红细胞生成性卟啉症(CEP)由尿卟啉原III合酶(UROS)缺陷导致卟啉蓄积,表现为皮肤光敏感和慢性溶血性贫血,目前仅对症治疗且不满意。研究在CEP细胞模型和小鼠模型中评估铁螯合剂去铁酮通过抑制铁依赖的ALAS2表达减少卟啉生成的效果。结果显示去铁酮可降低ALAS2和IREB2表达、减少卟啉产生,并在CEP小鼠中逆转皮肤光敏感、改善溶血和铁过载,最高剂量组贫血完全纠正。

要点

  • 去铁酮在CEP患者CD34+来源红系培养中抑制ALAS2和IREB2表达并减少卟啉生成。
  • CEP小鼠饮用去铁酮(1或3 mg/mL)26周后红细胞和尿卟啉蓄积逐渐减少,皮肤光敏感逆转。
  • 最高剂量去铁酮组CEP小鼠溶血和铁过载改善,贫血完全纠正。

核心结论

  • 在小鼠和人源模型中发现,限铁可调节CEP表型,具有治疗潜力。

研究设计与样本

  • 研究在CEP人红系细胞模型(UROS缺陷红系细胞系及CEP患者外周血CD34+来源红系培养)和CEP小鼠模型中进行。
  • 小鼠经饮水给予去铁酮1或3 mg/mL,治疗26周。

主要发现

  • 去铁酮处理UROS缺陷红系细胞系和CEP患者CD34+来源红系培养,抑制铁依赖蛋白ALAS2和铁反应元件结合蛋白2表达,减少卟啉生成。
  • CEP小鼠经去铁酮(1或3 mg/mL饮水)治疗26周,红细胞和尿中卟啉蓄积逐渐减少,皮肤光敏感逆转。
  • 最高剂量去铁酮组CEP小鼠溶血和铁过载改善,贫血完全纠正。

关键数值与推荐

  • 去铁酮饮水浓度1或3 mg/mL,治疗26周。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Congenital erythropoietic porphyria (CEP) is an inborn error of heme synthesis resulting from uroporphyrinogen III synthase (UROS) deficiency and the accumulation of nonphysiological porphyrin isomer I metabolites. Clinical features are heterogeneous among patients with CEP but usually combine skin photosensitivity and chronic hemolytic anemia, the severity of which is related to porphyrin overload. Therapeutic options include symptomatic strategies only and are unsatisfactory. One promising approach to treating CEP is to reduce the erythroid production of porphyrins through substrate reduction therapy by inhibiting 5-aminolevulinate synthase 2 (ALAS2), the first and rate-limiting enzyme in the heme biosynthetic pathway. We efficiently reduced porphyrin accumulation after RNA interference-mediated downregulation of ALAS2 in human erythroid cellular models of CEP disease. Taking advantage of the physiological iron-dependent posttranscriptional regulation of ALAS2, we evaluated whether iron chelation with deferiprone could decrease ALAS2 expression and subsequent porphyrin production in vitro and in vivo in a CEP murine model. Treatment with deferiprone of UROS-deficient erythroid cell lines and peripheral blood CD34+-derived erythroid cultures from a patient with CEP inhibited iron-dependent protein ALAS2 and iron-responsive element-binding protein 2 expression and reduced porphyrin production. Furthermore, porphyrin accumulation progressively decreased in red blood cells and urine, and skin photosensitivity in CEP mice treated with deferiprone (1 or 3 mg/mL in drinking water) for 26 weeks was reversed. Hemolysis and iron overload improved upon iron chelation with full correction of anemia in CEP mice treated at the highest dose of deferiprone. Our findings highlight, in both mouse and human models, the therapeutic potential of iron restriction to modulate the phenotype in CEP.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Blouin JM, Ged C, Lalanne M, et al. Iron chelation rescues hemolytic anemia and skin photosensitivity in congenital erythropoietic porphyria. Blood. 2020. PMID: 32678895. doi:10.1182/blood.2020006037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。